The in vivo experiments in this study also demonstrated that the BsAbs containing an anti-CD3 Fab have longer retention times on the surfaces of T cells (Fig. 5B), resulting in better anti-cancer efficacy in human tumor-bearing SCID mice models (Fig. 7). Here, FANCB is linked to neoplasm.